Pfizer CEO: We didn't delay vaccine results until after election

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/File Photo

(Reuters)


1 photo
Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (Reuters) — Drugmaker Pfizer "didn't conspire with anyone" to delay releasing efficacy results for the COVID-19 vaccine it developed with German partner BioNTech SE until after the U.S. presidential election, Chief Executive Albert Bourla said at a New York Times conference on Tuesday.

Bourla also said the company has already hit the required safety milestone for the vaccine's phase 3 trial, which is two months of data from around half of the study's roughly 44,000 participants. He said the company is currently preparing that data for submission.

(Reporting by Michael Erman; Editing by Chris Reese)

© Copyright Thomson Reuters 2020

Photos

Most recent Business stories

Related topics

Reuters
    KSL.com Beyond Business
    KSL.com Beyond Series

    KSL Weather Forecast

    KSL Weather Forecast
    Play button